# US 2020/0348310 A1 · Srm methods in alzheimer's disease and neurological disease assays

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0348310 A1
- Document ID: US20200348310A1
- Status: Published application
- Kind: A1
- Application number: 16/703,027
- Filed: 2019-12-04
- Published: 2020-11-05
- Earliest claimed: 2012-04-05
- Assignees: Biodesix, Inc.
- Applicants: Biodesix, Inc.
- Inventors: Paul E. Kearney; Xiao-Jun Li; Clive Hayward
- Web page: https://patentgrep.com/patent/US20200348310A1

## CPC

- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 2800/2821: Alzheimer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are methods for developing selected reaction monitoring mass spectrometry (LC-SRM-MS) assays.

## Claims

### Claim 1

A multiplexed LC-SRM-MS assay for the measurement of a plurality of proteins in a single sample comprising:
a) generating a set of optimal peptides and corresponding transitions for each protein monitored;
b) optimizing the collision energy for each transition such that interference among the transitions monitored is avoided;
c) selecting a set of transitions that have the greatest peak areas are monitored for each of the proteins, and wherein the selected transitions do not interfere with the ions in the sample;
d) monitoring the detected set of transitions for each protein in the sample, there by measuring a plurality of proteins in the sample.

### Claim 2 (depends on 1)

The assay of claim 1, wherein each monitored peptide
(i) has a monoisotopic mass of 700-5000 Da; and
(ii) does not contain a cysteine or a methionine.

### Claim 3 (depends on 1)

The assay of claim 1, wherein the transitions for each peptide
(i) have one of the four most intense b or y transition ions;
(ii) has m/z values of at least 30 m/z above or below those of a precursor ion;
(iii) do not interfere with transitions from other peptides; and
(iv) represent transitions due to breakage of peptide bond at different sites of the protein.

### Claim 4 (depends on 1)

The assay according to claim 1, wherein the peptides do not include any peptide that is bounded by KK, KR, RK or RR, either upstream of downstream in the corresponding protein sequence.

### Claim 5 (depends on 1)

The assay according to claim 1, wherein each peptide of said set of peptides is unique to the corresponding protein.

### Claim 6 (depends on 1)

The assay according to claim 1, wherein the peptides do not include peptides which were observed in post-translational modified forms.

### Claim 7 (depends on 1)

The assay according to claim 1, wherein each set of peptides is prioritized according to one or more of the following ordered set of criteria:
(a) unique peptides first, then non-unique;
(b) peptides with no observed post-translational modifications first, then those observed with post-translational modifications;
(c) peptides within the mass range 800-3500 Da first, then those outside of 800-3500 Da; and
(d) sorted by decreasing number of variant residues.

### Claim 8 (depends on 7)

The assay according to claim 7, wherein each set of peptides is prioritized according to all of the ordered set of criteria.

### Claim 9 (depends on 1)

The assay according to claim 1, wherein each prioritized set of peptides contains 1-5 peptides.

### Claim 10 (depends on 1)

The assay according to claim 1, wherein the two best peptides per protein and the two best transitions per peptide are selected based on experimental data resulting from LC-SRM-MS analysis of one or more of the following experimental samples: a biological disease sample, a biological control sample, and a mixture of synthetic peptides of interest.

### Claim 11 (depends on 10)

The assay according to claim 10, wherein the biological disease and biological control samples are processed using an immunodepletion method prior to LC-SRM-MS analysis.

### Claim 12 (depends on 11)

The assay according to claim 11, wherein the experimental samples contain internal standard peptides.

### Claim 13 (depends on 11)

The assay according to claim 11, wherein the LC-SRM-MS analysis method specifies a maximum of 7000 transitions, including transitions of the internal standard peptides and transitions.

### Claim 14 (depends on 1)

The assay according to claim 1, wherein the top two transitions per peptide are selected according to one or more of the following criteria:
(1) the transitions exhibit the largest peak areas measured in either of the two biological experimental samples;
(2) the transitions are not interfered with by other ions;
(3) the transitions do not exhibit an elution profile that visually differs from those of other transitions of the same peptide;
(4) the transitions are not beyond the detection limit of both of the two biological experimental samples; and
(5) the transitions do not exhibit interferences.

### Claim 15 (depends on 1, 12)

The assay according to claim 1, wherein the top two peptides per protein are selected according to one or more of the following criteria:
(1) one or more peptides exhibit two transitions according to claim 12 and represent the largest combined peak areas of the two transitions according to claims 12; and
(2) one or more peptides exhibit one transition according to claim 12 and represent the largest combined peak areas of the two transitions according to claim 12.

### Claim 16 (depends on 1)

An assay developed according to the method of claim 1.
